MindMed 2021 Year-End Conference Call and Earnings: Big Updates for MNMD Stock

Hey Psychedelic Investors! There’s been so much news this week that we decided to split “This Week In Psychedelic Stocks” in 2 parts. This segment is entitled “HUGE Studies Released: Psychedelics About to TAKE OVER the Stock market?” for a reason. The News we present will have major implications Psychedelic Stocks like MindMed (MMED /MMEDF/ MMQ), Compass Pathways (CMPS) and more.

In this episode, there’s lots of news for the psychedelic industry writ large. We’ll start up with three different studies that were released in the first week of April.

1. The Effects of Treating Depression with Psilocybin
2. Taking Psychedelics in a Ritual Setting
3. Microdosing study

After covering the pertinent aspects of these studies, we’ll take a look at Americans’ ability to buy Horizons’ ETF and finally we’ll give you some updates on some decriminalization efforts.

So that’s it for This Week in Psychedelic Stocks fellow psychedelic investors!

I hope you guys found some value in this and I’ll keep you posted for more changes!

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor

If you want to collaborate shoot us an email at: thepsychedelicinvestor@gmail.com

Music: www.bensound.com
https://benzinga.grsm.io/jameshallifa
​…
​
https://benzinga.grsm.io/thepsychedel
​…
​Timestamps:
0:00​ – Intro
1:24 – Effects of Treating Depression with Psilocybin
4:03 – Effects of Taking Psychedelics in A Ritual Setting
7:23 – Exploring the relationship between microdosing, personality & emotional insight
9:36 – Americans May be able to invest in Horizon’s ETF
11:42 – Progress on California’s bill that would LEGALIZE Possession of Psychedelics
12:57 – Massachusetts Approves Psychedelics Decimalization

General thoughts. We’ve been covering decriminalization and legalization efforts for almost two months now and EVERY WEEK, we see a new state or city starting to understand that psychedelics may be beneficial to society and may be able to treat mental illnesses such as depression, anxiety, ADHD, etc. On top of that, every week, we see study after study releasing promising results on the benefits of psychedelics to treat such mental maladies. If this is not proof that the SHROOM BOOM is real, what is? As more studies are released, it’ll only become more clear that psychedelics such as psilocybin, MDMA, DMT, LSD, etc may be able to disrupt a TRILLION dollar industry and us psychedelic investors might as well extract two-fold benefits : a. getting massive returns on investment and b. contributing to make the world a better place.

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#MindMed​​​​ ​#psychedelics​​​​ #shroomboom

In today’s episode, we discuss :MindMed Stock Catalysts for 2021: NASDAQ, Clinical Trial Results and More (MMED / MMEDF).

2020 was a wild year for MindMed, with the company IPOing in March, at just over 20c/ share, all prices in American currency. Then, the MindMed stock price shot up to a high of $4.37 in December, only to fall about 30% and consolidate around $3 a share in the new year.

But what will be the main catalysts for MindMed and its stock going forward in 2021? Put another way, what are the events and dates that shareholders and potential investors should circle on their calendars?

In this episode, we are going to talk about several catalysts to look out for
1. MindMed’s Nasdaq uplisting
– When to expect MindMed to join the Nasdaq?
– Is MindMed’s uplisting a sure thing?
-What will happen to MindMed stock if/when the company gets uplisted?

2. Clinical trials wrapping up, and data being released by MindMed
– Important dates MindMed investors should circle in their calendars
3. MindMed’s quarter end financial reporting
4. MindMed conference calls

Unknown Catalysts for Mindmed:
1. Clinical trials expansions
2. Financial agreements

** Also, on the 20th of January, Kevin O’Leary and Jr Rahn went live discussing MindMed. For those who haven’t seen it, Jr mentioned a few extra catalysts we should be looking forward to which we will discuss in our next episode.

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com

https://www.prnewswire.com/news-releases/atai-life-sciences-announces-closing-of-125-million-series-c-financing-round-301178915.html

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#MindMed #MMED #MMEDF

Hey psychedelic investors, this week we have Big Updates on MindMed, Compass, NUMI TRYP, TRUFF, ATAI, SHRM and LOBE Sciences and some amazing Ayahuasca study results which are detrimental to DMT research and this molecule potential effects on depression and anxiety.

Timestamps:
0:00 – Intro
0:52- Effects of DMT, taken using the ayahuasca drink, on depression and anxiety
5:26 – MindMed ( MMED / MNMD / MMQ ) stared trading on NASDAQ
6:01 – MindMed finishes phase2a trials for Project LUCY
8:15 – Atai Life Sciences To IPO soon on the Nasdaq and plans to raise $100 million
9:17 – Compass Pathways ( CMPS) to raise $144 million dollars
10:35 – Numinus Wellness ( NUMI ) to begin phase 1 trial for naturally extracted psilocybin in their lab
12:15 TRYP Therapeutics (TRYP) to begin 2 phase 2a trials in 2021
13:50 – Champignon Brands (SHRM) to restart trading in Canada
14:31 – Lobe Sciences (LOBE) & Core one Labs ( CLABF) to create a Joint Venture
15:34 – Red Light Holland (TRUFF) has increased its points of sale by 144% and TRUFF and Halo Collective create Red Light Oregn, INC

Link to Numinus (NUMI) press release: https://www.newswire.ca/news-releases/numinus-announces-phase-1-clinical-trial-of-natural-psilocybin-mushroom-extraction-prepared-at-company-lab-879795202.html?fbclid=IwAR1SmpbsTmXLs-mEy3vsUtAGKKk_xpf3FxJB3n2C-55zGJjiF0naXRetoUs

Link to Compass Pathways (CMPS) : https://www.globenewswire.com/news-release/2021/04/27/2218191/0/en/COMPASS-Pathways-launches-proposed-public-offering.html https://ir.compasspathways.com/static-files/fe6cc477-a2ee-4b4a-bd46-8f8df0b62f30

Link To Atai life Sciences: https://www.atai.life/

Link To MindMed (MMED / MNMD / MMQ) https://mindmed.co/
Link to MindMed clinical trial: https://clinicaltrials.gov/ct2/show/NCT03153579?term=lsd+anxiety&draw=2&rank=1

Link to Red LIght Holland (TRUFF) : https://www.newsfilecorp.com/release/81879/Red-Light-Holland-and-Halo-Collective-Create-Red-Light-Oregon-Inc.-Forwarding-Intentions-to-Enter-Oregon-Medicinal-Psychedelic-Market
https://www.cnbc.com/2021/04/21/atai-ipo-peter-thiel-backed-psychedelics-firm-to-raise-100-million.html

Link to Champignon Brands (SHRM) : https://www.prnewswire.com/news-releases/champignon-brands-announces-revocation-of-cease-trade-orders-301275526.html

Link to DMT study: https://www.sciencedirect.com/science/article/pii/S2666915321000251?fbclid=IwAR1-0HC9fxkL2Z47TEubMGsrqKInj61xLvBK4OW_C3FEQgv5VomoCSoNeQo

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌

Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #PsychedelicStocks #numiStock

There were LOTS of general news important for the psychedelic industry as a whole and very important study results that will influence some of our favorite stocks such as MindMed (MMED / MNMD / MMQ) and Compass Pathways (CMPS)!

In today’s episode we’ll cover a new American psychedelic ETF which is hitting the market under ticker symbol PSY, some new psilocybin and LSD studies, whether MAPS will turn into a public company and some updates on the California and New York bills we have been covering for a while now.

Enjoy the episode!

Timestamps:
0:00 – Intro
0:40 – The First American Psychedelic ETF (PSY)
5:50 – MAPS Considering An IPO?
12:28 – Psilocybin Assisted-Therapy Is 4-Times More Effective Than Typical SSRIs
15:29 – New Study On How LSD Affects The Brain
21:08 – The California Senate Has Approved a Bill To Legalize the Possession Of Psychedelics Like Psilocybin And LSD
23:00 – New York Bill Proposes State-Sponsored Psychedelic Research Institute

Links:
New Psychedelic ETF (NYSE : PSY) :
https://www.defianceetfs.com/psy/
https://psychedelicspotlight.com/psy-first-u-s-psychedelic-etf/

Maps Considering An IPO?:
https://www.reddit.com/r/shroomstocks/comments/nqoy0z/maps_considering_ipo/
https://youtu.be/v2HycPpjf6Y

Study Shows Psilocybin Assisted-Therapy Is 4-Times More Effective Than Typical Antidepressants:
https://thedalesreport.com/psychedelics/study-shows-psilocybin-assisted-therapy-4-times-more-effective-than-typical-antidepressants/

New Study On How LSD Affects The Brain:
https://www.theguardian.com/science/2021/may/19/acid-test-scientists-show-how-lsd-opens-doors-of-perception

The California Senate Has Approved a Bill To Legalize the Possession Of Psychedelics Like Psilocybin And LSD:
https://www.marijuanamoment.net/california-senate-approves-bill-to-legalize-possession-of-psychedelics-like-psilocybin-and-lsd/

New York Bill Proposes State-Sponsored Psychedelic Research Institute:
https://psychedelicspotlight.com/new-york-bill-psychedelic-research-institute/

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌

Instagram: @thepsychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
Video editing: @themyaholy
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #PsychedelicStocks #MAPS